3D Cell Culture Market (Updated Version Available)

Key Market Overview:

Global 3D cell culture Market size was valued at USD 1,473.34 Million in 2022, registering a CAGR of 16.9% during the forecast period (2023-2030), and the market is projected to be worth USD 5,090.44 Million by 2030.

The 3D cell culture is an artificially generated environment in which biological cells interact with their surroundings in all three dimensions. The various benefits associated with 3D cell culture include superior physiological relevancy, a higher degree of structural complexity, and others. The key trends such as emphasis on the rising adoption of 3D cell culture in cancer cell research, and rising demand for organ transplantation & tissue engineering, are the key factors attributing to the growth of the 3D cell culture market.

For instance, in March 2021, Thermo Fisher Scientific launched the new Gibco Human Plasma-like Medium (HPLM), the first cell culture medium on the market that demonstrates the metabolic profile of human plasma that is designed to provide researchers with a realistic view of cell growth within the human body. Hence, the increasing focus on the development of advanced technology will trigger the growth of the 3D cell culture market in the upcoming years.

Global 3D cell culture Market Report Coverage:

Report Attributes	Report Details
Study Timeline	2017-2030
Market Size in 2030 (USD Million)	5,090.44 Million
CAGR (2023-2030)	16.9%
Base Year	2022
By Type	Scaffold-Based 3D Cell Cultures (Hydrogel, Micropatterned Surfaces, Others), Scaffold-Free 3D Cell Cultures (Hanging Drop Microplates, Microfluidic 3D Cell Culture, Others)
By Application	Tissue Engineering, Drug Discovery, Organs-On-Chips, Cancer Research, Others
By End User	Pharmaceutical & Biotech Companies, Contract Research Organizations, Academic & Research Institutes, Others
By Geography	Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia] Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey] North America [United States, Canada, Mexico] Middle East & Africa [GCC, North Africa, South Africa] South America [Brazil, Argentina, Columbia, Chile, Peru]
Key Players	Corning Incorporated, PELOBIOTECH GmbH, Merck KGaA, REPROCELL Inc., 3D Biotek LLC., Iwai North America Inc., Thermo Fisher Scientific Inc., Lonza, SYNTHECON, INCORPORATED, Lena Biosciences, Inc., Advanced BioMatrix (part of BICO)

Request Sample

Market Dynamics:

Driver:

3D cell culture model provides more accurate and predictive results compared to the traditional 2D cell culture system. The 3d cell culture efficiently demonstrates the in vivo environment. This ensures superior drug screening and toxicology studies. The demand for 3D cell culture is growing as pharmaceutical companies and researchers prioritize more reliable and efficient drug discovery and toxicology methods. For instance, in August 2021, Amerigo Scientific introduced a new range of 3D cell culture products, which are utilized in research applications. The product is ideal for applications in medicine, drug discovery, and tissue engineering. Thus, recent product launches from industry players are driving the global 3D cell culture market growth.

Restraint:

The higher cost associated with the maintenance and implementation of 3D cell culture is posing a bottleneck for market growth. For instance, 3D cell culture systems often require standardized equipment, material, and reagents, which can drive up the overall cost. The high cost of 3D cell culture can limit its adoption, particularly in resource-constrained settings or for small research laboratories.

Hence, the higher maintenance and implementation cost related to the 3D cell culture is restraining the growth of the market.

Opportunities:

The 3D cell culture technique provides a suitable environment for the growth and differentiation of the stem cell. Thus, ensuring the development of more advanced steam cell-based therapies. The expansion of steam cell-based therapies creates opportunities for the use of 3D cell culture in their development and manufacturing. For instance, in February 2023, Corning Life Sciences developed a 3D cell culture technology and reinforces its strong commitment to innovation in the technology in the upcoming years.

Therefore, the increasing focus on developing innovative technology for the use of 3D cell culture in stem cells will create a lucrative growth opportunity for the market during the projected forecast period.

Global 3D Cell Culture Market Segmentation:



By Type:

The type segment is classified into scaffold-based 3D cell cultures and scaffold-free 3D cell cultures. The scaffold-based 3D cell culture segment accounted for the highest market share in the global 3D cell culture market. Scaffold-based 3D cell culture involves the growing of cells in the presence of support. The support can be in the form of hard polymer material-based supports and hydrogel-based supports are ideal models for culturing primary patient-derived cancer cells. For instance, in July 2023, CD BioSciences, a biotechnology company in the United States launched scaffold-based technologies to assist researchers in achieving organotypic co-culture and simulating layered tissue structures. Hence, the advancement of scaffold-based 3D cell culture is favoring the growth of the segment.

However, the scaffold-free 3D cell cultures segment is projected to grow at the fastest CAGR during the forecast period. This is due to the rising product innovations associated with scaffold-free 3D cell cultures, which are favoring segment growth.

By Application:

The application segment is classified into tissue engineering, drug discovery, organs-on-chips, cancer research, and others. In 2022, The drug discovery segment accounted for the highest market share in the global 3D cell culture market. The use of 3D cell culture in drug discovery is growing as it offers a more realistic representation of the human tissues, ensures superior prediction of drug efficacy and toxicity, and efficient prediction of drug efficacy and toxicity, disease modeling capabilities. For instance, in March 2021, Thermo Fisher Scientific, based in the United States introduced a cell culture medium that demonstrates the metabolic profile of human plasma. The product aids researchers with a realistic view of the growth of the cell in the human body. Henceforth, the above factors contribute to the increasing adoption of 3D cell culture in drug discovery as researchers seek more reliable and efficient methods for developing and identifying effective drug candidates.

However, the cancer research segment is projected to grow at the fastest CAGR during the forecast period. This is due to the rising research and development activities associated with the study of cancer.

By End-use:

The end-user segment is classified into pharmaceutical & biotech companies, contract research organizations, academic & research institutes, and others. In 2022, pharmaceutical & biotech companies segment accounted for the highest market share in the global 3D cell culture market. The continuous research and development in advanced technology of 3D cell culture has increased the use of 3D cell culture in pharmaceutical and biotech companies. For instance, in May 2022, Israel Biotech Fund Collaboration Framework Agreement and Lonza formed a partnership to provide aid to Biologics and Small Molecules Development and manufacturers for pharmaceutical and biotechnology companies in Israel. Thus, research and development activities will increase in the pharmaceutical and biotechnology companies. As a result, the above factor contributes to the increasing adoption of 3D cell culture in drug development as companies strive for more efficient and effective methods to identify and develop safe and efficacious drug candidates, thereby driving the market growth of the segment.

However, the academic & research institutes segment is projected to grow at the fastest CAGR during the forecast period. This is due to the rising development of new academic & research institutes at the global level.

By Region:

By region, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. In 2022, North America accounted for the highest market share in the 3D cell culture market, with the U.S. being a major contributor to the market. The United States is focusing on R&D and has been making significant investments in research on 3D cell culture for the past few years. This has resulted in technological advancements in the country. For instance, in July 2023, Merck invested USD 23 million to increase cell culture media production in Kansas, United States. The company will add 9,100 sq m2 of lab space and production capability to produce cell culture media. Hence, the rising emphasis on creating advanced cell culture models and methodologies is expected to be the significant factor driving market growth in the region.



However, the Asia Pacific region is projected to grow at the fastest CAGR during the forecast period. This is due to the presence of major players, advancement in 3D cell culture, and others.

Global 3D Cell Culture Market Competitive Landscape:

The global 3D cell market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the market include-

• Corning Incorporated
• PELOBIOTECH GmbH
• Merck KGaA
• REPROCELL Inc.
• 3D Biotek LLC.
• Iwai North America Inc.,
• Thermo Fisher Scientific Inc.
• Lonza
• SYNTHECON, INCORPORATED
• Lena Biosciences, Inc.
• Advanced BioMatrix (part of BICO)

Recent Developments

• In June 2020, CELLINK and Lonza collaborated to offer 3D bioprinting solutions to optimize access to 3-dimensional cell cultures workflows. The solution combines CELLINKs 3D bioprinting instruments and bioinks with Lonzas primary cells and culture media, to meet the needs of cell biologists for enhanced bioprinting of complex 3D human tissue constructs.